Fentanyl was created in 1960 by Belgian chemist Paul Janssen, one of the most prolific drug developers in pharmaceutical history, who was searching for a painkiller more potent and faster-acting than the options available at the time. His work produced a synthetic opioid roughly 100 times stronger than morphine, and the drug went on to reshape surgery, pain management, and eventually the landscape of drug addiction.
Why Paul Janssen Built a New Painkiller
In the late 1950s, Janssen and his team at Janssen Pharmaceutica in Belgium began experimenting with chemical variations of meperidine (sold as Demerol), a widely used painkiller that had significant drawbacks. Meperidine worked, but it was relatively weak, wore off quickly, and caused problematic side effects. Janssen’s goal was to find new chemical structures in the meperidine family that delivered stronger pain relief with a faster onset.
Janssen was a remarkably productive medicinal chemist, credited with creating approximately 80 drugs over his career. His approach involved systematically tweaking the molecular structure of existing compounds and testing each variation for analgesic activity. By the early 1960s, this process yielded fentanyl, which proved to be far more potent than anything in its class. He received a U.S. patent for the compound in 1964.
How the Drug Works in the Body
Fentanyl produces its effects by binding to mu-opioid receptors, the same receptors that morphine targets. But fentanyl fits these receptors differently. Research has shown that in addition to occupying the standard binding site shared by older opioids, fentanyl can move deeper into the receptor and lock into a secondary binding position. This dual interaction helps explain why fentanyl triggers such a powerful response at tiny doses.
The drug is also highly lipophilic, meaning it dissolves easily in fat. This property allows it to cross from the bloodstream into the brain much faster than morphine, producing rapid onset of pain relief (and, dangerously, rapid onset of respiratory depression). One milligram of fentanyl delivered intravenously is equivalent to roughly 100 milligrams of oral morphine.
The Chemistry Behind Fentanyl Synthesis
Fentanyl is a fully synthetic opioid, meaning it doesn’t come from the opium poppy. It’s built entirely from chemical precursors in a laboratory through a multi-step process. Two key intermediate chemicals sit at the center of fentanyl production: NPP (N-phenethyl-4-piperidinone) and ANPP (4-anilino-N-phenethylpiperidine). These compounds serve as the molecular backbone that gets transformed into fentanyl through a series of chemical reactions.
There are multiple known routes to synthesize fentanyl. The two most referenced are the Janssen method (based on the original developer’s approach) and the Siegfried method, which became widely used in illicit manufacturing because it was straightforward and well-documented. In the Siegfried route, NPP is converted to ANPP, and then the final step involves attaching a specific chemical group (an acylation reaction) to complete the fentanyl molecule. Forensic chemists can actually distinguish between these synthesis routes by analyzing the trace impurities left behind, which act like a chemical fingerprint revealing how a particular batch was made.
The relative simplicity of fentanyl synthesis compared to plant-derived opioids is a major reason it became so prevalent in the illicit drug supply. It requires no poppy fields, no harvest seasons, and no large agricultural operations. A competent chemist with access to precursor chemicals can produce it in a modestly equipped lab.
Controlling the Precursors
Recognizing that blocking access to raw materials was one way to limit illicit production, international bodies moved to restrict fentanyl’s key building blocks. In 2017, the United Nations placed NPP and ANPP under international controls as regulated drug precursors. China, which the U.S. Department of State identified as the base for more than half of global suppliers of these chemicals, controlled both precursors in 2018.
These restrictions had a predictable consequence: illicit manufacturers adapted. To get around controls on NPP and ANPP, labs shifted to the Janssen method or other synthesis routes that use different starting materials. A new generation of alternative precursors emerged, including compounds like 4-AP, 1-BOC-4-ANPP, and 4,4-piperidinediol, most of which remain unregulated in many countries.
From Operating Room to Pain Patch
Fentanyl received FDA approval in the United States in 1968, initially as an injectable solution for use during and after surgery. It was marketed under the brand name Sublimaze. George De Castro, an anesthesiologist working near Brussels, was likely the first clinician to evaluate fentanyl in a surgical setting. He experimented with using it as a component of anesthesia, combining it with sedatives and nitrous oxide. A technique called neurolept anesthesia, which paired fentanyl with another drug called droperidol, became a standard approach in operating rooms.
For its first two decades, fentanyl was almost exclusively a hospital drug, delivered by injection and used in controlled surgical environments. That changed in the late 1980s when Alza Corporation developed a transdermal patch that could deliver fentanyl through the skin at a steady rate over 72 hours. The technology used ethanol in a gel matrix to help the drug penetrate the skin barrier. Early clinical trials ran in the late 1980s, and the patch reached the market in 1990 under the brand name Duragesic, manufactured by Johnson & Johnson. It was designed for patients with chronic pain who needed around-the-clock relief. Duragesic dominated the transdermal drug market, hitting peak sales above $2 billion in 2004.
Additional delivery forms followed over the years, including lozenges, nasal sprays, and dissolving tablets, each designed for specific clinical situations like breakthrough cancer pain. Fentanyl is classified as a Schedule II controlled substance under the Controlled Substances Act, placing it in the same category as oxycodone and methadone: recognized medical value, but high potential for abuse and dependence.
Why Potency Became the Problem
The same properties that made fentanyl revolutionary in medicine made it catastrophic as a street drug. Its extreme potency means the difference between an active dose and a lethal dose is measured in micrograms, quantities invisible to the naked eye. Its synthetic nature means production can scale rapidly without agricultural constraints. And its fast onset means overdose can occur within minutes of exposure.
Illicitly manufactured fentanyl is now the leading cause of overdose deaths in the United States, a crisis driven not by diverted pharmaceutical supplies but by clandestine labs producing the drug from unregulated precursor chemicals. The compound Paul Janssen designed to make surgery safer became, six decades later, the deadliest drug in the country.